BAW 2881

BAW 2881 is a vascular endothelial growth factor receptor (VEGFR) inhibitor (IC₅₀s = 0.82, 0.037, and 0.42 µM for hVEGFR1, 2, and 3, respectively).¹ It inhibits Tie2 and RET with IC₅₀ values of 0.65 and 0.41 µM, respectively, but demonstrates IC₅₀ values great than 10 µM toward a large panel of additional kinases.¹ BAW 2881 was shown to block VEGF-A-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells and lymphatic endothelial cells in vitro.¹ In a mouse model of psoriasis, both oral and topical administration of BAW 2881 reduced psoriasis-like inflammation in ear skin.¹ Topical application of BAW 2881 also reduced VEGF-A-induced vascular permeability and inhibited contact hypersensitivity reactions and UV-B-induced erythema in the skin of domestic pigs.¹

WARNING This product is not for human or veterinary use.

1. Halin, C., Fahrngruber, H., Meingassner, J.G., et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am. J. Pathol. 173(1), 265-277 (2008).